Clinical Scorecard: Medical debt linked to higher late-stage cancer rates

At a Glance

Key Highlights

• Each 10-percentage-point increase in county medical debt prevalence was associated with 5.15 additional late-stage lung cancer cases per 100,000 person-years.
• Smaller adjusted increases per 10-percentage-point increase in medical debt prevalence were reported for late-stage head and neck, colorectal, melanoma, cervical, kidney and renal pelvis, and bladder cancers.
• Compared with counties in the lowest debt quartile, those in the highest quartile had 39% higher late-stage lung, 14% higher late-stage colorectal, and 24% higher late-stage cervical cancer incidence.
• Late-stage breast cancer incidence was not associated with medical debt in the primary analysis; higher medical debt was associated with lower recorded late-stage prostate cancer incidence.
• The ecological, cross-sectional design precluded causal or patient-level conclusions.

Guideline-Based Recommendations

Diagnosis

• The analysis evaluated nine cancers with screening recommendations or recognizable early signs or symptoms; it did not assess individual diagnostic practices.

Management

• The researchers called for longitudinal studies incorporating individual-level risk factors and health care use to clarify the relationship between medical debt and cancer stage at diagnosis.

Monitoring & Follow-up

• The study assessed age-adjusted all-stage and late-stage incidence rates per 100,000 person-years for 2017–2021, in relation to county medical debt prevalence measured in 2016.

Risks

• Associations may reflect residual confounding by socioeconomic factors, health care resources, or state policies; causality cannot be inferred.
• County averages may obscure within-county disparities, and the study could not determine whether people with medical debt were the same individuals diagnosed with cancer.
• The collections-based measure did not capture all forms of medical borrowing or the amount of debt relative to household finances.

Patient & Prescribing Data

No individual patients were assessed. The study included county-level data from 2,958 US counties; 185 of 3,143 counties were excluded because medical debt data were unavailable.

No treatments or prescribing were evaluated. The study reported associations between county medical debt prevalence and cancer incidence by stage.

Clinical Best Practices

• The study’s ecological, cross-sectional design precluded causal or patient-level conclusions.
• The authors noted possible residual confounding, within-county disparities obscured by county averages, and limitations in the collections-based debt measure.
• The authors called for longitudinal studies incorporating individual-level risk factors and health care use to clarify the relationship between medical debt and cancer stage at diagnosis.

Related Resources & Content

• JAMA Network Open